U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H15ClN6O.CH4O3S
Molecular Weight 414.867
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BIIB021 MESYLATE

SMILES

CS(O)(=O)=O.COC1=C(C)C=NC(CN2C=NC3=C(Cl)N=C(N)N=C23)=C1C

InChI

InChIKey=QQYUAUPJJLOCHU-UHFFFAOYSA-N
InChI=1S/C14H15ClN6O.CH4O3S/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21;1-5(2,3)4/h4,6H,5H2,1-3H3,(H2,16,19,20);1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula C14H15ClN6O
Molecular Weight 318.761
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

BIIB021 binds in the ATP-binding pocket of Hsp90, interferes with Hsp90 chaperone function, and results in client protein degradation and tumor growth inhibition. Hsp90 is overexpressed in many types of cancer and acts to stabilize malignancy producing oncoproteins. Therefore, inhibition of Hsp90 with BIIB021 leads to the degradation of oncoproteins that drive malignancy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P07900
Gene ID: 3320.0
Gene Symbol: HSP90AA1
Target Organism: Homo sapiens (Human)
1.7 nM [Kd]
Conditions

Conditions

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1439 ng/mL
600 mg 1 times / day single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BIIB021 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2942 ng × h/mL
600 mg 1 times / day single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BIIB021 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In a phase II clinical trial, breast cancer patients were treated with either 100 mg twice daily + exemestane 25 mg once per day for 28 days, or 450 mg three times weekly + exemestane 25 mg once per day.
Route of Administration: Oral
BIIB021 was investigated as an inhibitor of heat shock protein 90 (Hsp90) alone and in combination with triptolide (TPL) on T-cell acute lymphoblastic leukemia. The cell viability of Human T-ALL cell line Molt-4 was measured using MTT assay. Molt-4 cells were treated with BIIB021 (50-800 nmol/L) which inhibited the cell growth in a dose-dependent manner. The IC50 value was 384.6 and 301.8 nmol/L, respectively, at 48 and 72 h.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:50:44 UTC 2023
Edited
by admin
on Wed Jul 05 23:50:44 UTC 2023
Record UNII
389JLN330H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BIIB021 MESYLATE
Common Name English
(6-CHLORO-9-(4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YLMETHYL)-9H-PURIN-2-YL)AMINE MESILATE
Systematic Name English
(6-CHLORO-9-(4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YLMETHYL)-9H-PURIN-2-YL)AMINE MESYLATE
Systematic Name English
BIIB-021 MESILATE
Common Name English
9H-PURIN-2-AMINE, 6-CHLORO-9-((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)-, METHANESULFONATE
Systematic Name English
BIIB 021 MESYLATE
Code English
9H-PURIN-2-AMINE, 6-CHLORO-9-((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)-, METHANESULPHONATE
Systematic Name English
BIIB021 MESILATE
Common Name English
BIIB 021 MESILATE
Common Name English
BIIB-021 MESYLATE
Code English
Code System Code Type Description
FDA UNII
389JLN330H
Created by admin on Wed Jul 05 23:50:44 UTC 2023 , Edited by admin on Wed Jul 05 23:50:44 UTC 2023
PRIMARY
CAS
1225041-97-3
Created by admin on Wed Jul 05 23:50:44 UTC 2023 , Edited by admin on Wed Jul 05 23:50:44 UTC 2023
PRIMARY
PUBCHEM
56843312
Created by admin on Wed Jul 05 23:50:44 UTC 2023 , Edited by admin on Wed Jul 05 23:50:44 UTC 2023
PRIMARY
DRUG BANK
DBSALT002182
Created by admin on Wed Jul 05 23:50:44 UTC 2023 , Edited by admin on Wed Jul 05 23:50:44 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY